NCT05659654 is a Phase 1, PHASE2 clinical trial of Ursodeoxycholic acid in COVID-19, sponsored by Institute of Hematology & Blood Diseases Hospital, China.

Who is sponsoring NCT05659654?

NCT05659654 is sponsored by Institute of Hematology & Blood Diseases Hospital, China.

What drugs are being tested in NCT05659654?

Interventions in NCT05659654: Ursodeoxycholic acid.

Is NCT05659654 still recruiting?

NCT05659654 is currently completed. Last updated 24 February 2025.

Last reviewed 2025-02-24 · How we verify

NCT05659654

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19)

Completed Phase 1, PHASE2 Last updated 24 February 2025

What this trial tests

Phase 1, PHASE2 trial testing Ursodeoxycholic acid in COVID-19 in 95 participants. Completed in 8 March 2023.

Timeline

16 December 2022

Primary endpoint
3 March 2023

8 March 2023

Quick facts

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	95
Start date	16 December 2022
Primary completion	3 March 2023
Estimated completion	8 March 2023
Sites	1 location across China

Drugs / interventions tested

Ursodeoxycholic acid — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Who can join

Adults 18 to 65, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of the efficacy and safety of ursodeoxycholic acid in blocking the transmission of infectious novel coronaviruses in a population of medical workers

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Health position paper and redox perspectives - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases.
Cuadrado A, Cazalla E, Bach A, Bathish B, et al · · 2025 · cited 9× · PMID 40059038 · DOI 10.1016/j.redox.2025.103569
Ursodeoxycholic acid and severe COVID-19 outcomes in a cohort study using the OpenSAFELY platform.
Costello RE, Waller KMJ, Smith R, Mells GF, et al · · 2024 · cited 2× · PMID 39562612 · DOI 10.1038/s43856-024-00664-y
Ursodeoxycholic acid and severe COVID-19 outcomes in people with liver disease: a cohort study using the OpenSAFELY platform
Costello RE, Jean Waller KM, Smith R, Mells GF, et al · · 2023 · DOI 10.1101/2023.12.11.23299191

Verify or expand the search:

Other trials of Ursodeoxycholic acid

Trials testing the same drug.

NCT06517862 — Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal Hyperbilirubinemia · Phase 4 · recruiting
NCT06091787 — Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration on Right Lobe Donor Hepatectomy · NA · completed
NCT05902468 — Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus · Phase 2, PHASE3 · unknown
NCT05467553 — A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection · Phase 2 · unknown
NCT05690646 — Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery · Phase 4 · unknown

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Institute of Hematology & Blood Diseases Hospital, China trials

Trials by the same sponsor.

NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05659654 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
Last refreshed: 24 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05659654.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing